Advertisement
Research Article

Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials

  • Rémy Boussageon,

    Affiliation: Department of General Medicine, Université Claude Bernard Lyon 1, Lyon, France

    X
  • Irène Supper,

    Affiliation: Department of General Medicine, Université Claude Bernard Lyon 1, Lyon, France

    X
  • Theodora Bejan-Angoulvant,

    Affiliations: Service de Pharmacologie Clinique, Centre Hospitalier Régional et Universitaire de Tours, France, UMR 7292, CNRS, Université François Rabelais, Tours, France

    X
  • Nadir Kellou,

    Affiliation: Department of General Medicine, Université Claude Bernard Lyon 1, Lyon, France

    X
  • Michel Cucherat,

    Affiliations: UMR 5558, CNRS, Laboratoire de Biométrie et Biologie Évolutive, Villeurbanne, France, Université Claude Bernard Lyon 1, Lyon, France

    X
  • Jean-Pierre Boissel,

    Affiliations: UMR 5558, CNRS, Laboratoire de Biométrie et Biologie Évolutive, Villeurbanne, France, Université Claude Bernard Lyon 1, Lyon, France

    X
  • Behrouz Kassai,

    Affiliations: UMR 5558, CNRS, Laboratoire de Biométrie et Biologie Évolutive, Villeurbanne, France, Université Claude Bernard Lyon 1, Lyon, France, Clinical Investigation Centre, INSERM CIC201, Lyon, France, Department of Clinical Pharmacology, Hospices Civils de Lyon, Lyon, France

    X
  • Alain Moreau,

    Affiliation: Department of General Medicine, Université Claude Bernard Lyon 1, Lyon, France

    X
  • François Gueyffier,

    Affiliations: UMR 5558, CNRS, Laboratoire de Biométrie et Biologie Évolutive, Villeurbanne, France, Université Claude Bernard Lyon 1, Lyon, France, Clinical Investigation Centre, INSERM CIC201, Lyon, France, Department of Clinical Pharmacology, Hospices Civils de Lyon, Lyon, France

    X
  • Catherine Cornu mail

    catherine.cornu@chu-lyon.fr

    Affiliations: UMR 5558, CNRS, Laboratoire de Biométrie et Biologie Évolutive, Villeurbanne, France, Université Claude Bernard Lyon 1, Lyon, France, Clinical Investigation Centre, INSERM CIC201, Lyon, France, Department of Clinical Pharmacology, Hospices Civils de Lyon, Lyon, France

    X
  • Published: April 10, 2012
  • DOI: 10.1371/journal.pmed.1001204

About the Authors

Rémy Boussageon, Irène Supper, Nadir Kellou, Alain Moreau
Department of General Medicine, Université Claude Bernard Lyon 1, Lyon, France
Theodora Bejan-Angoulvant
Service de Pharmacologie Clinique, Centre Hospitalier Régional et Universitaire de Tours, France
Theodora Bejan-Angoulvant
UMR 7292, CNRS, Université François Rabelais, Tours, France
Michel Cucherat, Jean-Pierre Boissel, Behrouz Kassai, François Gueyffier, Catherine Cornu
UMR 5558, CNRS, Laboratoire de Biométrie et Biologie Évolutive, Villeurbanne, France
Michel Cucherat, Jean-Pierre Boissel, Behrouz Kassai, François Gueyffier, Catherine Cornu
Université Claude Bernard Lyon 1, Lyon, France
Behrouz Kassai, François Gueyffier, Catherine Cornu
Clinical Investigation Centre, INSERM CIC201, Lyon, France
Behrouz Kassai, François Gueyffier, Catherine Cornu
Department of Clinical Pharmacology, Hospices Civils de Lyon, Lyon, France

Corresponding Author

Email: catherine.cornu@chu-lyon.fr

Competing Interests

MC received fees for consulting from BMS and Servier. MC also received fees for speaking from AstraZeneca. All other authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: RB TBA CC FG. Performed the experiments: IS. Analyzed the data: RB CC TBA NK MC JPB BK AM. Wrote the first draft of the manuscript: RB TBA FG CC. Contributed to the writing of the manuscript: RB TBA NK AM FG CC. ICMJE criteria for authorship read and met: RB IS TBA NK MC JPB BK AM FG CC. Agree with manuscript results and conclusions: RB IS TBA NK MC JPB BK AM FG CC.